T2 mapping as a predictor of nonperfused volume in MRgFUS treatment of desmoid tumors.
Int J Hyperthermia
; 36(1): 1272-1277, 2019.
Article
en En
| MEDLINE
| ID: mdl-31822140
ABSTRACT
Objective:
The objective of this study was to develop an alternative method of non-contrast monitoring of tissue ablation during focused ultrasound treatment. Desmoid tumors are benign but locally aggressive soft tissue tumors that arise from fibroblast cells. Magnetic resonance-guided focused ultrasound (MRgFUS) has emerged as an alternative to conventional therapies, showing promising results in reduction of tumor volume without significant side effects. The gold-standard assessment of the reduction of viable tumor volume post-treatment is non-perfused volume (NPV) and evaluation of NPV is typically performed with post-treatment gadolinium enhanced MR imaging. However, as gadolinium cannot be repeatedly administered during treatments, there is a need for alternative non-contrast monitoring of the tissue to prevent over and under treatment.Methods:
Double-echo and multi-echo images were acquired before, during and after the MRgFUS treatment. T2 maps were generated with an exponential fit and T2 maps were compared to post-treatment post-contrast images.Results:
In all five MRgFUS treatment sessions, T2 mapping showed excellent qualitative agreement with the post-contrast NPV.Conclusions:
T2 mapping may be used to visualize the extent of ablation with focused ultrasound and can be used as a predictor of NPV prior to the administration of contrast during the post-treatment assessment.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Mapeo Encefálico
/
Imagen por Resonancia Magnética
/
Fibromatosis Agresiva
/
Ultrasonido Enfocado de Alta Intensidad de Ablación
Tipo de estudio:
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
Idioma:
En
Revista:
Int J Hyperthermia
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2019
Tipo del documento:
Article